metformin has been researched along with saroglitazar in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatt, J; Dunbar, RL; Parmar, DV; Parmar, K; Rastogi, A; Thacker, HP | 1 |
| Li, J; Wu, WH; Yan, Q; Zhang, H; Zhang, ZY; Zhao, Y | 1 |
1 review(s) available for metformin and saroglitazar
| Article | Year |
|---|---|
PPAR-alpha/gamma agonists, glucagon-like peptide-1 receptor agonists and metformin for non-alcoholic fatty liver disease: A network meta-analysis.
Topics: Glucagon-Like Peptide-1 Receptor; Humans; Metformin; Network Meta-Analysis; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors | 2023 |
1 trial(s) available for metformin and saroglitazar
| Article | Year |
|---|---|
Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Phenylpropionates; Placebos; Postprandial Period; PPAR alpha; PPAR gamma; Pyrroles; Triglycerides | 2020 |